Focus on non-hospitalized patients based on prior data supporting Leukine’s role in improving lung function and enhanced COVID-19 specific immune response

LEXINGTON, MA – April 29, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the SCOPE clinical trial, a randomized, placebo-controlled, double-blind phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in 400 non-hospitalized COVID-19 patients (NCT04707664) at higher risk for progression to more severe COVID-19.  ...